Insight the C-Site Pocket Conformational Changes Responsible for Sirtuin 2 Activity Using Molecular Dynamics Simulations

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Sakkiah, Sugunadevi ^a,b   Arooj, Mahreen ^a   Cao, Guang Ping ^a   Lee, Keun Woo ^a  

^a Gyeongsang National University   (South Korea)

^b Gwangju Institute of Science and Technology (GIST)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ENZYME INHIBITOR; GLUTAMINE; HISTIDINE; NICOTINAMIDE ADENINE DINUCLEOTIDE; SIRTUIN 2;

ARTICLE; CONTROLLED STUDY; DEACETYLATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME INHIBITION; ENZYME MODIFICATION; ENZYME STRUCTURE; ENZYME SUBSTRATE; MOLECULAR DYNAMICS; PROTEIN ASSEMBLY; SIMULATION;

ENZYME ACTIVATION; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; MUTATION, MISSENSE; PROTEIN CONFORMATION; SIRTUIN 2;

EID: 84875136775     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059278     Document Type: Article

References (52)

1. Kouzarides D, (2007) Chromatin modifications and their function. Cell. 124: 693-705.
2. Sakkiah S, Krishnamoorthy N, Gajendrarao P, Thangapandian S, Lee Y, et al. (2009) Pharmacophore modeling and virtual screening for SIRT1 activators. BKCS. 30: 1152-1156.
3. Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, et al. (2002) MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J. 21: 6236-6245.
4. Juan LJ, Shia WJ, Chen MH, Yang WM, Seto E, et al. (2000) Histone deacetylases specifically down-regulate p53-dependent gene activation. J. Biol. Chem. 274: 20436-20443.
5. Glozak MA, Sengupta N, Zhang X, Seto E, (2005) Acetylation and deacetylation of non-histone proteins. Gene. 363: 5-23.
6. Sauve AA, Wolberger C, Schramm VL, Boeke JD, (2006) The biochemistry of sirtuins. Annu. Rev. Biochem. 75: 1-13.
7. Michan S, Sinclair D, (2007) Sirtuins in mammals: Insights into their biological function, Biochemical J. 404: 1-13.
8. Du J, Jiang H, Lin H, (2009) Investigating the ADP-ribosyltransferase activity of sirtuins with NAD analogues and 32P-NAD. Biochem. 48: 2878-2890.
9. Marcia C, Haigis LP, Guarente P, (2006) Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction. Genes Dev. 20: 2913-2920.
10. Saunders LR, Verdin E, (2007) Sirtuins: Critical regulators at the crossroads between cancer and aging. Oncogene 26: 5489-5504.
11. Gan L, Mucke L, (2008) Paths of Convergence: Sirtuins in Aging and Neurodegeneration. Neuron. 58: 10-14.
12. Milne JC, Denu JM, (2008) The Sirtuin family: therapeutic targets to treat diseases of aging. Current Opinion in Chemical Biology 12: 11-17.
13. Outeiro TF, Marques O, Kazantsev A, (2008) Therapeutic role of sirtuins in neurodegenerative disease. Biochimica et Biophysica Acta. 1782: 363-369.
14. North BJ, Marshall BL, Borra MT, Denu JM, Verdin E, (2003) The Human Sir2 Ortholog, SIRT2, Is an NAD+-Dependent Tubulin Deacetylase. Molecular Cell 11: 437-444.
15. Jin YH, Kim YJ, Kim DW, Baek KH, Kang BY, et al. (2008) Sirt2 interacts with 14-3-3 β/γ and down-regulates the activity of p53. Biochemical and Biophysical Research Communications 368: 690-695.
16. Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I, (2005) Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol. Biol. Cell 16: 4623-4635.
17. Westphal CH, Dipp MA, Guarente L, (2007) A therapeutic role for sirtuins in diseases of aging?. Trends in biochemical sciences 32: 555-560.
18. Finnin MS, Donigian JR, Pavletich NP, (2001) Structure of the histone deacetylase SIRT2. Nat Struct Mol Biol. 8: 621-625.
19. Zhao W, Kruse JP, Tang Y, Jung SY, Qin J, et al. (2008) Negative regulation of the deacetylase SIRT1 by DBC1. Nature 451: 587-590.
20. Heltweg B, Gatbonton T, Schuler AD, Posakony J, Li H, et al. (2006) Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Can. Res. 66: 4368-4377.
21. Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, et al. (2007) Sirtuin 2 inhibitors rescue α-synuclein-mediated toxicity in models of Parkinson's disease. Science 317: 516-519.
22. Guarente L, (2006) Sirtuins as potential targets for metabolic syndrome. Nature 444: 868-874.
23. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, et al. (2007) Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450: 712-716.
24. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, et al. (2006) Resveratrol Improves Mitochondrial Function and Protects against Metabolic Disease by Activating SIRT1 and PGC-1±. Cell 127: 1109-1122.
25. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, et al. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 444: 337-342.
26. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, et al. (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425: 191-196.
27. Yoshida T, Kadota Y, Hitaoka S, Kori E, Horikawa Y, et al. (2009) Expression and molecular dynamics studies on effect of amino acid substitutions at Arg344 in human cathepsin A on the protein local conformation. Biochim. Biophys. Acta. 1794: 1693-1699.
28. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucleic Acids Research 28: 235-242.
29. Brooks B, Bruccoleri R, Olafson B, States D, Swaminathan S, et al. (1983) CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem. 4: 187-217.
30. Smellie A, Teig SL, Towbin P, (1995) Poling: Promoting conformational variation. J. Comp. Chem. 16: 171-187.
31. Berendsen HJC, Van Der Spoel D, Van Drunen R, (1995) GROMACS: A message-passing parallel molecular dynamics implementation. Comp. Phy. Comm. 91: 43-56.
32. Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, et al. (2005) GROMACS: Fast, flexible, and free. J. Comp. Chem. 26: 1701-1718.
33. Lindahl E, Hess B, Van Der Spoel D, (2001) GROMACS 3.0: a package for molecular simulation and trajectory analysis. J. Mol. Mod. 7: 306-317.
34. Van Gunsteren WF, Berendsen HJC (1987) Groningen Molecular Simulation (GROMOS) Library Manual, BIOMOS b.v., Groningen.
35. Van Gunsteren WF, Billeter SR, Eising AA, Hunenberger PH, Kruger P, et al. (1996) Biomolecular Simulation: The GROMOS96 Manual and User Guide; vdf Hochschlverlag AG an der ETZ Zurich and BIOMOS b.v.: Zurich, Groningen.
36. Aalten DMF, Bywater R, Findlay JBC, Hendlich M, Hooft RWW, et al. (1996) PRODRG, a program for generating molecular topologies and unique molecular descriptors from coordinates of small molecules. J. Computer-Aided Molecular Design 10: 255-262.
37. Berendsen HJC, Postma JPM, Van Gunsteren WF, Hermans J (1981) Interaction models for water in relation to protein hydration. Intermol. Forces 331-342.
38. Sakkiah S, Thangapandian S, Park C, Son M, Lee KW, (2012) Molecular Docking and Dynamcis Simulation, Receptor-based Hypothesis: Application to Identify Novel Sirtuin 2 Inhibitors. Chem. Biol. Drug Des. 80: 315-327.
39. Sakkiah S, Chandrasekaran M, Lee Y, Kim S, Lee KW, (2012) Molecular modeling study for conformational changes of sirtuin 2 due to substrate and inhibitor binding. J. Biomol. Str. Dyn. 30: 235-254.
40. Miyamoto S, Kollman P, (1992) Settle: An analytical version of the SHAKE and RATTLE algorithm for rigid water models. J. Comput. Chem. 13: 952-962.
41. Hess B, Bekker H, Berendsen HJC, Fraaije JGEM, (1997) LINCS: A linear constraint solver for molecular simulations. J. Comp. Chem. 18: 1463-1472.
42. Schreiber H, Steinhauser O, (1992) Taming cut-off induced artifacts in molecular dynamics studies of solvated polypeptides: The reaction field method. J. Mol. Biol. 228: 909-923.
43. Paul ES, Wilfred FVG, (1994) Consistent dielectric properties of the sample point charge and extended simple point charge water models at 277 and 300K. J. Chem. Phys. 100: 3169-3174.
44. Berendsen HJC, Postma JPM, Gunsteren WFV, DiNola A, Haak JR, (1984) Molecular dynamics with coupling to an external bath. J. Chem. Phy. 81: 3684-3690.
45. Darden T, York D, Pedersen L, (1993) Particle mesh Ewald: An N. log(N) method for Ewald sums in large systems. J. Chem. Phys. 98: 10089-10092.
46. Humphrey W, Dalke A, Schulten K, (1996) VMD: Visual molecular dynamics. J. Mol. Grap. 14: 33-38.
47. W.L.DeLano, PyMol User's Guide (2004) DeLano Scientific LLC, San Francisco.
48. Sakkiah S, Baek A, Lee KW, (2012) Pharmacophore modeling and molecular dynamics simulation to identify the critical chemical features against human sirtuin 2 inhibitors. J. Mol. Str. 1011: 66-75.
49. Sakkiah S, Arooj M, Kumar MR, Eom SH, Lee KW. Identification of Inhibitor Binding Site in Human Sirtuin 2 Using Molecular Docking and Dynamics Simulations. Plos One. In Press.
50. Zhao K, Harshaw R, Chai X, Marmorstein R, (2004) Structural basis for nicotinamide cleavage and ADP-ribose transfer by NAD(+)-dependent Sir2 histone/protein deacetyases. PNAS. 101: 8563-8568.
51. Avalos JL, Bever KM, Wolberger C, (2005) Mechanism of Sirtuin Inhibition by Nicotinamide: Altering the NAD+ Cosubstrate Specificity of a Sir2 Enzyme. Molecular Cell 17: 855-868.
52. Baker NA, Sept D, Joseph S, Holst MJ, McCammon JA, (2001) Electrostatics of nanosystems: Application to microtubules and the ribosome. PNAS. 98: 10037-10041.